Ajovy

RSS

fremanezumab

Authorised
This medicine is authorised for use in the European Union.

Overview

Ajovy is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. The active substance contained in Ajovy is fremanezumab.

This EPAR was last updated on 17/04/2019

Authorisation details

Product details
Name
Ajovy
Agency product number
EMEA/H/C/004833
Active substance
fremanezumab
International non-proprietary name (INN) or common name
fremanezumab
Therapeutic area (MeSH)
Migraine Disorders
Anatomical therapeutic chemical (ATC) code
N02
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Teva GmbH
Date of issue of marketing authorisation valid throughout the European Union
28/03/2019
Contact address

Graf-Arco-Straße 3
D-89079 Ulm
Germany

Product information

28/03/2019 Ajovy - EMEA/H/C/004833 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ANALGESICS

Therapeutic indication

Ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Assessment history

How useful was this page?

Add your rating
Average
1 rating